Biosimilars set to benefit patients and the NHS
Adalimumab comes off patent
Today marks the European patent expiry for the biologic Adalimumab (Humira), which is prescribed in hospitals for conditions including rheumatoid arthritis, inflammatory bowel disease and psoriasis.
This means that equally safe and effective 'biosimilar' versions can now be prescribed.
Commenting on the news, Jatinder Harchowal, Chair of the RPS Hospital Expert Advisory Group, said:
"The availability of biosimilar versions of Adalimumab is good news for patients and the NHS.
“Biosimilars are already being used for other conditions and have the same efficacy and same high levels of safety and quality as the original biological agent. Patients can therefore be confident they are still getting the best treatment but it is very important that any change in treatment is made in consultation with the patient, so they are fully informed about biosimilars.
“The reduced costs associated with the use of a biosimilar help the NHS get best value from medicines whilst maintaining the same clinical efficacy and safety profile.”